IDH1 and neoplasm: The production of a specific oncometabolite by IDH-mutant tumours has also led to studies measuring 2-hydroxyglutarate in body fluids, such as plasma and urine [14], and by imaging techniques [8] to assess disease progression and/or response to therapy.